CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
[^14C]-LY2835219drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01913314
NCT01913314Phase 1Completed
CompareCT.gov

Disposition of [^14C]-LY2835219 Following Oral Administration in Healthy Subjects

Eli Lilly and Company·interventional·Posted Aug 1, 2013·Updated Jan 7, 2019

In Brief

A Phase 1 clinical trial evaluating [^14C]-LY2835219 for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered. In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected. This study will last about 3 weeks for each participant, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 1, 2013
Enrollment StartAug 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.9 years ago

Interventions

[^14C]-LY2835219drug

Administered as oral solution